Login to Your Account



Earnings Roundup


Thursday, May 9, 2013

• Pacira Pharmaceuticals Inc. reported total revenues for the quarter ended March 31, 2013, were $11.6 million compared with $7.8 million for the quarter ended March 31, 2012. The increase in revenues was primarily driven by $10.4 million of net product sales of Exparel (bupivacaine liposome injectable suspension) in postsurgical analgesia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription